ArticleCase reports in neurological medicine2026
Radiographic Enhancing Progression Without Molecular or Histologic Progression in IDH-Mutant Grade 2 Astrocytoma Treated With an IDH Inhibitor: A Case Report.
Article in Case reports in neurological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiographic Enhancing Progression Without Molecular or Histologic Progression in IDH-Mutant Grade 2 Astrocytoma Treated With an IDH Inhibitor: A Case Report.Case reports in neurological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system (CNS) World Health Organization (WHO) Grade 2 isocitrate dehydrogenase (IDH)-mutant astrocytomas are classified as low-grade gliomas with typically slow growth for many years followed by eventual malignant transformation and death. Here, we present a case of a patient with an IDH-mutant Grade 2 astrocytoma who developed early radiographic tumor progression per Response Assessment in Neuro-Oncology (RANO) 2.0 as evidenced by new enhancement on MRI T1 postcontrast 4 months after initiation of an IDH inhibitor. Subsequent re-resection, one month later (or five months postinitiation of ivosidenib treatment), of the enhancing signal retained the Grade 2 designation without any histological or molecular progression per CNS WHO 2021 criteria. Specifically, the Ki-67 proliferative index remained stable at approximately 2%, and copy number alterations were largely unchanged, including no
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.